These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12552862)

  • 41. Bacterial degradation of risperidone and paliperidone in decomposing blood.
    Butzbach DM; Stockham PC; Kobus HJ; Sims DN; Byard RW; Lokan RJ; Walker GS
    J Forensic Sci; 2013 Jan; 58(1):90-100. PubMed ID: 22994980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.
    Sherwin CM; Saldaña SN; Bies RR; Aman MG; Vinks AA
    Ther Drug Monit; 2012 Oct; 34(5):535-44. PubMed ID: 22929407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection.
    Aravagiri M; Marder SR; Wirshing D; Wirshing WC
    Pharmacopsychiatry; 1998 May; 31(3):102-9. PubMed ID: 9657237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.
    Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia A
    Ther Drug Monit; 2001 Jun; 23(3):223-7. PubMed ID: 11360029
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of age and gender on risperidone plasma concentrations.
    Aichhorn W; Weiss U; Marksteiner J; Kemmler G; Walch T; Zernig G; Stelzig-Schoeler R; Stuppaeck C; Geretsegger C
    J Psychopharmacol; 2005 Jul; 19(4):395-401. PubMed ID: 15982995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum concentrations and side effects in psychiatric patients during risperidone therapy.
    Olesen OV; Licht RW; Thomsen E; Bruun T; Viftrup JE; Linnet K
    Ther Drug Monit; 1998 Aug; 20(4):380-4. PubMed ID: 9712460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010.
    Bowskill SV; Handley SA; Fisher DS; Flanagan RJ; Patel MX
    Ther Drug Monit; 2012 Jun; 34(3):349-55. PubMed ID: 22569353
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of risperidone and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV.
    Mandrioli R; Mercolini L; Lateana D; Boncompagni G; Raggi MA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jan; 879(2):167-73. PubMed ID: 21183412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service.
    Castberg I; Spigset O
    Ther Drug Monit; 2005 Feb; 27(1):103-6. PubMed ID: 15665755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma risperidone levels and clinical response in patients with first-episode psychosis.
    Verma SK; Tan CH; Chan YH; Chong SA
    J Clin Psychopharmacol; 2005 Dec; 25(6):609-11. PubMed ID: 16282849
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
    Yasui-Furukori N; Mihara K; Takahata T; Suzuki A; Nakagami T; De Vries R; Tateishi T; Kondo T; Kaneko S
    Br J Clin Pharmacol; 2004 May; 57(5):569-75. PubMed ID: 15089809
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels.
    Lane HY; Chiu WC; Chou JC; Wu ST; Su MH; Chang WH
    J Clin Psychiatry; 2000 Mar; 61(3):209-14. PubMed ID: 10817107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
    Kakihara S; Yoshimura R; Shinkai K; Matsumoto C; Goto M; Kaji K; Yamada Y; Ueda N; Ohmori O; Nakamura J
    Int Clin Psychopharmacol; 2005 Mar; 20(2):71-8. PubMed ID: 15729081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HPLC-DAD determination of plasma levels of the antipsychotic risperidone and its main metabolite for toxicological purposes.
    Raggi MA; Bugamelli F; Sabbioni C; Saracino MA; Petio C
    J Sep Sci; 2005 Feb; 28(3):245-50. PubMed ID: 15776926
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders.
    Vanwong N; Prommas S; Puangpetch A; Hongkaew Y; Nuntamool N; Nakorn CN; Ngamsamut N; Limsila P; Sukasem C
    J Clin Lab Anal; 2016 Nov; 30(6):1236-1246. PubMed ID: 27346210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum concentrations of paliperidone versus risperidone and clinical effects.
    Nazirizadeh Y; Vogel F; Bader W; Haen E; Pfuhlmann B; Gründer G; Paulzen M; Schwarz M; Zernig G; Hiemke C
    Eur J Clin Pharmacol; 2010 Aug; 66(8):797-803. PubMed ID: 20358189
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative determination of risperidone, paliperidone and olanzapine in human serum by liquid chromatography-tandem mass spectrometry coupled with on-line solid-phase extraction.
    Ruan CJ; Guo W; Zhou M; Guo GX; Wang CY; Li WB; de Leon J
    Biomed Chromatogr; 2018 Jul; 32(7):e4209. PubMed ID: 29473184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers.
    Lee DY; Lee KU; Kwon JS; Jang IJ; Cho MJ; Shin SG; Woo JI
    Psychopharmacology (Berl); 1999 Jun; 144(3):272-8. PubMed ID: 10435394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: a pharmacological puzzle.
    Railton CJ; Kapur B; Koren G
    Ther Drug Monit; 2005 Oct; 27(5):558-61. PubMed ID: 16175125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.
    Du J; Zhang A; Wang L; Xuan J; Yu L; Che R; Li X; Gu N; Lin Z; Feng G; Xing Q; He L
    J Psychopharmacol; 2010 Jul; 24(7):1115-20. PubMed ID: 19395426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.